The sports psychiatrist and psychiatric medication

被引:25
作者
Reardon, Claudia L. [1 ,2 ,3 ]
机构
[1] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA
[2] Univ Hlth Serv, Counseling Serv, 333 East Campus Mall, Madison, WI 53715 USA
[3] Univ Hlth Serv, Consultat Serv, 333 East Campus Mall, Madison, WI 53715 USA
关键词
Athletes; psychiatric medication; sports; sports psychiatry; stimulants; 5-HT REUPTAKE INHIBITOR; EXERCISE PERFORMANCE; PHYSICAL PERFORMANCE; PROLONGED EXERCISE; DAYTIME ALERTNESS; PSYCHOMOTOR; RESPONSES; ZOPICLONE; LITHIUM; PAROXETINE;
D O I
10.1080/09540261.2016.1190691
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
There are several critical factors to consider in prescribing psychiatric medications to athletes. In addition to the usual considerations when prescribing any psychotropic agent to any patient, the prescriber in this case should pay careful attention to: (1) potential negative impact of the medication on athletic performance, (2) potential performance-enhancing effects, and (3) potential safety risks. This paper describes an updated review of relevant research findings and considerations in the above areas within various categories of psychiatric medications. Many methodological concerns exist with the studies that have examined psychotropic medication use by athletes. These include: small sample sizes; use of the medication in dosing strategies (e.g. single dose) that do not replicate how they are usually taken in the real world; use of primarily male subjects only; use of performance measures (e.g. subtraction, multitask) in some studies that may not align with physical demands experienced by athletes in their natural athletic environments; and not using athletes who actually have the psychiatric disorder or symptom the medication was designed to treat. Despite these concerns, data currently available provide at least some guidance for clinicians wishing to make informed decisions about psychotropic prescribing for their athlete-patients.
引用
收藏
页码:606 / 613
页数:8
相关论文
共 38 条
[1]  
[Anonymous], 2015, NCAA BANNED DRUGS ME
[2]   The relevance of melatonin to sports medicine and science [J].
Atkinson, G ;
Drust, B ;
Reilly, T ;
Waterhouse, J .
SPORTS MEDICINE, 2003, 33 (11) :809-831
[3]  
CHANDLER JV, 1980, MED SCI SPORT EXER, V12, P65
[4]   PSYCHOMOTOR, PULMONARY AND EXERCISE RESPONSES TO SLEEP MEDICATION [J].
CHARLES, RB ;
KIRKHAM, AJT ;
GUYATT, AR ;
PARKER, SP .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (02) :191-197
[5]   Attention deficit/hyperactivity disorder and psychopharmacologic treatments in the athlete [J].
Conant-Norville, DO ;
Tofler, IR .
CLINICS IN SPORTS MEDICINE, 2005, 24 (04) :829-+
[6]  
Cowan DA, 1994, Oxford textbook of sports medicine, P314
[7]   EXERCISE AND ANTIDEPRESSANT SERUM LEVELS [J].
DEZWAAN, M .
BIOLOGICAL PSYCHIATRY, 1992, 32 (02) :210-211
[8]   Comparative effects of zopiclone and loprazolam on psychomotor and physical performance in active individuals [J].
Grobler, LA ;
Schwellnus, MP ;
Trichard, C ;
Calder, S ;
Noakes, TD ;
Derman, WE .
CLINICAL JOURNAL OF SPORT MEDICINE, 2000, 10 (02) :123-128
[9]   The International Athlete-Advances in Management of Jet Lag Disorder and Anti-Doping Policy [J].
Herman, Daniel ;
MacKnight, John M. ;
Stromwall, Amy E. ;
Mistry, Dilaawar J. .
CLINICS IN SPORTS MEDICINE, 2011, 30 (03) :641-+
[10]   THE EFFECTS OF ANXIOLYTICS ON CFF [J].
HOLMBERG, G .
PHARMACOPSYCHIATRIA, 1982, 15 :49-53